Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EVM14 Alone and With Pembrolizumab in Advanced Solid Tumors
NCT07095868Phase 2Recruiting
- Sponsor
- Everest Medicines
- Start
- Nov 2025
- Primary completion
- Nov 2029
- Modality
- Lipid-based Nanoparticles, Therapeutic Vaccines, mRNA Therapeutics
- Countries
- 2
01
Overview
Phase 2, randomised, open-label trial of EVM14 in solid tumor (7 arms), sponsored by Everest Medicines. Primary endpoints: Incidence and severity of adverse events, Incidence of dose-limiting toxicities at 28 days and 1 more. Started Nov 2025; status: recruiting.
02
Drugs
EVM14
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT07095868.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07095868.